Key regions: Germany, United States, India, Japan, United Kingdom
For the past years, Anti-Rheumatic Drugs has been the second largest section of the Pharmaceuticals market. The market size is projected to decrease because of biosimilar competition for market-leading products.
Customer preferences: Patients suffering from rheumatoid arthritis and other autoimmune diseases prefer drugs that provide long-term relief from pain and inflammation. They also prefer drugs that have fewer side effects and are easy to administer. In recent years, biologic drugs have gained popularity among patients due to their effectiveness in managing symptoms and improving quality of life.
Trends in the market: The market is expected to see a shift towards biosimilars, which are expected to provide cost-effective alternatives to expensive biologic drugs. Personalized medicine is gaining more and more importance. The market is also expected to see a shift towards self-administration of drugs, which is expected to improve patient convenience and reduce healthcare costs. The use of traditional Chinese or Japanese medicine is also expected to play a certain role in the treatment of rheumatoid arthritis. In India, the market is also expected to see a shift towards the use of Ayurvedic medicine for the treatment of rheumatoid arthritis
Local special circumstances: The market size is projected to decrease because of biosimilar competition for the market-leading product Humira by AbbVie. The drop in 2019 reflects the emergence of biosimilars outside of the U.S., while the decrease expected to occur towards the end of the time series is linked to the loss of exclusivity in the U.S.
Underlying macroeconomic factors: The Anti-Rheumatic Drugs market is expected to be driven by the increasing prevalence of rheumatoid arthritis and other autoimmune diseases worldwide. The market is also expected to be driven by the growing demand for advanced biologic drugs and biosimilars. The market is expected to face challenges due to the high cost of biologic drugs and the increasing availability of generic drugs. The market is also expected to face challenges due to the lack of reimbursement policies and the increasing competition from traditional medicine.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
